

MEDIA STATEMENT

PHILOGEN SPA ANNOUNCES PARTICIPATION IN THE “3rd Shanghai Tech-SIAIS BioForum”, 07 – 10 NOVEMBER 2016, SHANGHAI, CHINA

[Philogen S.p.A.](#) and its fully owned subsidiary [Philochem AG](#), announce their participation to the “3rd ShanghaiTech-SIAIS BioForum” that will take place at Jumeirah Himalayas Hotel in Shanghai from November 7 to November 10, 2016.

The main theme of the four-day congress will be “Advances and Perspectives in Integrative Biology of Cellular Processes”.

Prof. Dr. Dario Neri, Swiss Federal Institute of Technology Zurich, co-founder and Chairman of the scientific advisory board of Philogen, will give a talk on “DNA-encoded chemical libraries”. The presentation is scheduled for Wednesday, November 09th.

For additional news and press release topics, visit: <http://www.philogen.com/en/news/>

About the Philogen group

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com
